A percutaneous arterial closure protocol can decrease complications after endovascular interventions in vascular surgery patients  by Goodney, Philip P. et al.
From the Society for Clinical Vascular Surgery
A percutaneous arterial closure protocol can
decrease complications after endovascular
interventions in vascular surgery patients
Philip P. Goodney, MD, Robert W. Chang, MD, and Jack L. Cronenwett, MD, Lebanon, NH
Objective: Complications following percutaneous femoral access are a significant source of morbidity and cost in patients
undergoing peripheral vascular interventions. Our purpose in this study is to determine if access complications could be
reduced by the use of a standardized protocol.
Methods:We studied prospectively 210 consecutive patients in our vascular surgery practice undergoing peripheral arterial
interventions via percutaneous retrograde femoral access. First, we prospectively collected data to determine current
outcomes during a 4-month observation phase. Based on these experiences, we designed and implemented a uniform
arterial closure protocol, with closure device use guided by sheath size, arterial calcification, and previous groin scarring.
Our main outcome measures were major complications (need for operation) or minor complications (access site bleeding
or hematoma). Outcomes were compared between the two phases using chi-squared analysis and analysis of variance
(ANOVA).
Results: In the observation phase, 119 patients underwent 140 arterial punctures, and in the postprotocol phase, we
performed 112 punctures in 91 patients. Between the observation and postprotocol phases, patient demographics were
similar; average sheath size was unchanged (sheaths over 6F 6% vs 8%, respectively, P  .55), and percentage of patients
receiving heparin did not change significantly (76% vs, 86%, P  .08). No major complications occurred in either the
observation or the postprotocol phases. While 24 minor complications occurred in the observation phase, only seven
minor complications occurred in the postprotocol phase (17% vs 7%, P< .02). Closure device use decreased with protocol
implementation (57% to 32%, P < .01), but closure device failures also decreased from 23% to 7% (P < .01).
Conclusions: Process improvement, achieved by instituting a standardized percutaneous arterial closure protocol based on
selective closure device use guided by sheath size, arterial calcification, and previous access scarring. Implementation of
our protocol resulted in a decrease in the incidence of minor complications at the access site and refined patient selection
for closure device use. ( J Vasc Surg 2008;48:1481-88.)Endovascular therapy now represents a major compo-
nent in the treatment of peripheral vascular disease,1 largely
due its less-invasive nature. However, endovascular therapy
requires arterial access, often via large diameter sheaths, and
difficulties may be encountered in obtaining hemostasis.2
While manual compression followed by a period of bedrest
offers an effective mechanism to achieve hemostasis, it
comes with a significant cost in terms of patient discomfort
and need for monitoring after the procedure,3 The alterna-
tive to manual compression is use of a closure device. These
devices often utilize suture-mediated closure or collagen
plugs to obtain local hemostasis, and have reported shorter
time to hemostasis, time to ambulation, and time to dis-
charge as compared to manual compression.3,4
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these two modalities (manual compression or a closure
device) achieves the best outcomes. Most large series of
closure device use report a 5% to 10% complication rate,
most commonly bleeding, pseudoaneurysm, hematoma
formation, and thrombosis,5 even in patients without pe-
ripheral vascular disease. A recent systematic review of
closure devices compared with manual compression dem-
onstrated only marginal evidence that closure devices are
effective, and the authors raised concerns that the devices
increased the risk of hematoma and pseudoaneurysm.4
Additionally, randomized trials of closure devices have
raised further debate about which patients are appropriate
candidates for closure devices,6-10 especially in terms of
femoral artery calcification. Lastly, while closure devices
have been studied in large groups of patients, patients with
peripheral vascular disease have largely been excluded from
these trials;3 only one randomized study has purposefully
tested a closure device in patients with peripheral vascular
disease.9
Given the lack of consensus for the best method of
achieving arterial closure after percutaneous endovascular
interventions in patients with peripheral vascular disease,
we sought to study and optimize our method of percuta-
neous arterial closure. To accomplish this task, we em-
ployed a quality improvement initiative. Quality improve-
ment, a concept described by W. Edwards Deming in the
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management theory that relies upon continuous planning,
implementation, evaluation of results, and action to im-
prove the results of a system. The goal and purpose of our
quality improvement initiative was to standardize, and
hopefully improve the processes of care surrounding per-
cutaneous arterial closure in vascular surgery patients un-
dergoing percutaneous arterial interventions.
METHODS
We conducted a prospective study divided into two
phases: observation and postintervention. Prior to the
study onset, we received Institutional Review Board ex-
emption from the Institutional Review Board of Dart-
mouthMedical School. All patients undergoing percutane-
ous arterial interventions in the Section of Vascular Surgery
via retrograde femoral access were deemed eligible for
inclusion in our study. We excluded antegrade femoral,
brachial, carotid, and other types of access.
Observation phase. The observation phase was com-
posed of two elements: data collection on current practices
in our group, and a survey of surgeon preferences in our
group. First, we designed a database to collect patient and
procedure-level information about each patient enrolled in
our study. Individual variables were chosen based on review
of randomized trials of closure device use and systematic
reviews of arterial closure methods.4,9 We collected data on
each retrograde femoral puncture, with the unit of analysis
being the artery. For example, if a patient had bilateral
percutaneous access for iliac stenting, each puncture
counted as one artery, and the patient would enter two
arteries independently into the study. We then used this
database to characterize our arterial closure methods across
the nine attending surgeons performing endovascular pro-
cedures in this study. We collected this data prospectively
over a 4-month period, from January 1, 2007 through
April 30, 2007. This period was termed the “observation
phase”.
In addition to the observation phase, we sought to
define the influences on the decision-making used in access
closure by the vascular surgeons in the group. At our
facility, surgeons had several options for closure. Manual
compression alone was available, as was manual compres-
sion with a Syvek hemostatic patch (Marine Polymer Tech-
nologies, Danvers, Mass). The closure devices available at
the time of our study were the Perclose Proglide (Abbott,
Abbott Park, Ill) as well as the Starclose (Abbott, Abbott
Park, Ill). Closure devices could also be combined with the
use of a hemostatic patch if deemed necessary.
To describe our patterns in arterial closure, we de-
signed and administered a survey regarding arterial closure
preferences to the vascular surgery staff at our facility. First,
we noted that most vascular surgeons in our group prefer
manual compression of puncture sites following the use of
sheaths 5F and smaller. Observational data and these stated
preferences were highly correlated (nearly all surgeons in
our group preferred the use of manual compression when
using only a 5F sheaths, and nearly all surgeons performedmanual compression only when using a 5F sheath) in the
observational phase, no closure devices were used when
only a 5F sheath was used. Second, for sheaths 6F or larger,
closure devices were preferred for use in the absence of
arterial calcification or scarring from prior surgery or per-
cutaneous access. Manual compression times varied across
sheath size, from 10 to15 minutes for 5F sheaths, to up to
20 to 25minutes for sheaths 7F and over. While admittedly
little evidence exists for this these time intervals, we used
data from several prior studies to generatemanual compres-
sion guidelines.2,4,10 One of the principal investigators in
the study (P.G. or R.C.) was present and directly performed
each arterial puncture and closure in the observation phase
(as well as the postprotocol phase, as described below).
After our survey and the observation phase, our next
step was to construct a uniform protocol for percutaneous
arterial closure. The aforementioned information from our
survey, as well as prospective data collected as part of the
observation phase, and data from literature review was used
to design our Vascular Surgery Closure Protocol, shown in
Fig 1. Our literature review, survey and observation phase
data suggested that most decisions around arterial closure
depended upon sheath size, arterial artery calcifications,
and scarring or prior access in the groin. Therefore, we
designed our protocol around these three domains.
Following discussions with vascular surgeons, nurses,
and angiography technicians to familiarize them with the
project, we implemented our protocol on May 1, 2007.
The period from May 1 until July 15 was designated as the
“postprotocol” phase. This phase was distinct and exclusive
from the “observation” phase. In order to estimate how
many patients to enroll in each phase, we performed a
power analysis prior to starting the first segment of the
observation phase. If we presumed a complication rate of
15% in the observation phase, and a postprotocol compli-
cation rate of 7.5%, and a standard deviation of 20% we
calculated that we would have an 80% power to detect a
difference at a 0.05 level of significance with 112 arteries in
each group. We enrolled 140 arterial punctures in the
observation phase, and 112 arteries in the postprotocol
phase, and each closure was directly performed by one of
the primary investigators (P.G. and R.C.) during their
dedicated time performing specifically endovascular proce-
dures during fellowship training.
Postprotocol phase. In the postprotocol phase, we
enrolled all patients undergoing retrograde femoral punc-
ture in our vascular surgery closure protocol that was
designed at the conclusion of the observation phase. Com-
plications were divided into two groups: major and minor.
Major complications were defined as femoral artery bleed-
ing or thrombosis necessitating operative or angiographic
intervention. Minor complications were defined as access
site bleeding, or hematoma that required attention after the
initial closure process had concluded (ie, need for the
surgeon or nurse to take additional steps such as need for
additional compression, longer recovery room observation,
delay in discharge, hospital admission, or transfusion). We
utane
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observation phase and the postprotocol phase.
All surgeons in the group agreed to inclusion of their
patients in the closure protocol. Compliance to the proto-
col was 100%, and this is because all punctures and closures
were performed directly by the one of the two principal
investigators in the study (P.G. and R.C.). Data was re-
corded in our Access (Microsoft, Redmond Wash) data-
base, and outcomes were compared between the pre- and
postprotocol groups using STATA (STATA Corporation,
Fig 1. Vascular surgery percCollege Station, Tex). 2 analysis was used to comparecomplication rates, and P values .05 were considered
significant.
RESULTS
In the observation phase, between February 1, 2007,
and April 31, 2007, we enrolled 119 patients who under-
went 140 arterial punctures (99 patients had one puncture,
and 20 patients had multiple punctures). Similarly, in the
postprotocol phase, between May 1st, 2007 and July 15,
2007, we enrolled 91 patients who underwent 112 punc-
ous arterial closure protocol.tures (70 patients had one puncture, and 21 patients had
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shown in Table I. Both groups were similar in terms of age
and body mass index. Indications were similar across
groups as well, with most patients being treated for lower
extremity ischemia. In both groups, most patients were
treated with antiplatelet agents prior to the procedure.
While there were fewer patients in the postprotocol group
on aspirin alone, there were more patients in the postpro-
tocol treated with aspirin and Plavix.
Procedural characteristics are shown in Table II. Over-
all, sheath sizes were similar between the Observation and
postprotocol phases. While significantly more 9F sheaths
were used in the postprotocol phase, no complications
occurred in these patients. Heparin was utilized more com-
monly in the postprotocol phase, (86% vs 76%). However,
heparin was also more likely to be reversed with protamine
in the postprocedure phase (51% unreversed in the obser-
vation phase, 25% unreversed in the postprotocol phase).
Cases were also slightly longer in the postprotocol phase.
Closure device use decreased with protocol implementa-
tion (57% to 32%, P .01), but closure device failures also
decreased from 23% to 7% (P  .01) with protocol imple-
mentation.
As shown in Table III, time to hemostasis was slightly
longer in the postprotocol phase (11 minutes vs 16 min-
utes, P .0001). This effect persisted across closure types.
Table I. Patient characteristics
Observation p
na  140
n
Mean age 70.8  12
BMI 28.4
Male gender 82
Pedal pulse examination
Absent 18
Doppler signal only 86
Palpable 36
Indications
Carotid 15
Aortic arch 1
Claudication 51
Rest pain 15
Tissue loss 31
Renal 19
Mesenteric 3
Other 5
Periprocedure anticoagulation
INR over 2.0 10
Aspirin only 80
Plavix only 6
Aspirin and Plavix 45
No antiplatelet agent 9
Femoral artery characteristics
Calcified artery 42
Previous access or surgical scar 21
BMI, Body mass index.
an  number of arteries.
bAnalysis of variance (ANOVA) across type of pulse examination.In patients who did not receive a closure device, time tohemostasis was longer in the postprotocol phase by 4
minutes if the patient received only manual compression
(P .004), and by 1 minute if a hemostatic patch was used
Postprotocol phase
na  112
n % P value
68.0  12.2 .09
29.2 .30
% 71 63% .443
% 1 1%
% 95 85% .930b
% 16 14%
% 16 14% .419
% 0 0% .421
% 40 36% .919
% 13 12% .749
% 20 18% .402
% 13 12% .725
% 5 5% .185
% 2 2% —
% 2 2% .09
% 39 35%
% 2 2% .398
% 60 54%
% 9 9% .504
% 32 32% .634
% 14 14% .878
Table II. Procedural characteristics
Observation
phase
n 140
Postprotocol
phase
n  112
n % n % P value
Sheath size
5F 45 32% 44 39% .248
6F 87 62% 59 53% .157
Sheath size over 6F 8 6% 9 8% .551
7F 7 5% 3 3% .534
8F 1 1% 0 0% .419
9F 0 0% 4 4% .01
Heparin administered 107 76% 96 86% .08
Heparin not reversed with
protamine 71 51% 28 25% .0001
Case length over 1 hour 65 46% 67 62% .04
Closure device use
(excluding Syvek) 80 57% 36 32% .01
Perclose only 43 31% 21 19% .04
Starclose only 17 12% 0 0% .001
Perclose  Syvek 16 12% 10 9% .521
Starclose  Syvek 4 3% 4 4% .532
Closure device failure 32 23% 8 7% .01hase
%
.1
59
13
61
26
11
1
36
11
22
14
2
4
7
57
4
32
6
30
15(P  .261). In patients who received a closure device
and a
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postprotocol phase was longer by an average of 4 minutes.
Trends towards longer time to hemostasis were noted
across individual closure devices in the postprotocol phase,
but small numbers limit this analysis (Fig 2).
Periprocedural complication rates are shown in Table
IV. No major complications (need for surgery) occurred in
either the pre or postprotocol phase. However, in terms of
minor complications, in the observation phase, arterial
puncture resulted in 24 minor complications (17%). These
were comprised of 13 bleeding episodes and 11 hemato-
mas. In the postprotocol phase, minor complications de-
creased significantly to 7% (vs 17%, P  .02). In the
observation phase, complications necessitated additional
compression in most cases and observation in a monitored
setting in others. Three patients required hospital admis-
Table III. Time to hemostasis
Observation phase
n 140
Time to hemostasis n %
All patients 140 100%
Manual compression, no Syvek 32 22%
Any closure device (Syvek) 108 78%
Syvek only 28 20%
Perclose only 43 31%
Starclose only 17 12%
Perclose  Syvek 16 12%
Starclose  Syvek 4 3%
aP value noted is for 2 analysis of the time to hemostasis in minutes.
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Fig 2. Complications beforesion, and two of these required transfusion. However, inthe postprotocol phase, five patients required additional
compression, and three patients required further observa-
tion. No patients in the postprotocol phase required trans-
fusion or hospital admission.
DISCUSSION
Access complications following endovascular proce-
dures in vascular surgery patients represent an important
cause of periprocedural morbidity and cost.2,4,12 Our
protocol represents our effort to formalize the decision-
making process around arterial closure as well as improve
outcomes. Using prospectively collected data, literature
review, and a survey of vascular surgeons at our institution,
we designed and implemented a closure protocol based on
sheath size, arterial calcification, and previous access scar-
ring. We noted two changes after implementing our arterial
Postprotocol phase
n  112
utes n % minutes P valuea
112 100% 16 .0001
10 9% 18 .004
102 91% 15 .0001
66 59% 18 .261
.8 21 19% 9.4 .111
0 0% — n/a
.9 10 9% 13.8 .460
4 4% 9 .991
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ringclosure protocol. First, we noted a significant decrease in
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proved patient selection in use of closure devices. Though
we used fewer closure devices overall, these devices were
more often successful in achieving hemostasis.
Arterial closure following percutaneous access has re-
ceived considerable attention following coronary angiogra-
phy. However, relatively little investigation has occurred in
patients with peripheral vascular disease. Starnes et al eval-
uated a suture-mediated closure device specifically in
vascular surgery patients with femoral artery calcification
in a randomized trial comparing manual compression
with suture-mediated closure device in 102 patients.9
While they achieved hemostasis with a suture-mediated
closure device in 49 of 52 attempts, six complications
occurred, two of which were major and required operative
intervention. Mackrell et al described the use of a suture-
mediated closure device in 500 patients undergoing lower
extremity percutaneous revascularization.13 While the de-
vice was deployed successfully in 95% of patients, seven
major complications occurred, including one death from
retroperitoneal hemorrhage and three episodes of limb
ischemia, all of which required operative or lytic interven-
tion. Wilson et al described complications occurring in 10
patients following use of percutaneous arterial closure de-
vices in a vascular surgery practice, noting six arterial infec-
tions, all of which required operative, drainage, and four
patients required arterial reconstruction.14 Lastly, while
not focusing specifically on vascular surgery patients, a
systematic review of arterial puncture closure devices per-
formed in 2004 studied the results from randomized trials
of several different closure devices compared with manual
compression.4 This meta-analysis assimilated data from
over 4000 patients across 30 randomized trials, although
many of these trials were judged to be of poor method-
ologic quality. While time to hemostasis was overall shorter
if patients received a closure device (mean difference of 17
minutes, range 14 to 19 minutes), the risk of hematoma
Table IV. Periprocedural complications
Observation
phase
n  140
Postprotocol
phase
n  112
n % n % P value
Minor complication 24 17% 7 7% .02
Bleeding 13 9% 3 3% —
Hematoma 11 8% 4 3% —
Additional maneuvers 19 14% 6 7% .249
Compression 17 14% 5 5% —
Monitoring only 2 2% 1 1% —
Delay in discharge 12 9% 3 3% .120
1 h 2 2% — — —
1-2 h 2 2% 3 3% —
2-4 h 4 3% — — —
4 h 1 1% — — —
Hospital admission 3 2% — — —
Need for transfusion 2 1% 0 — .250was nearly twice as high (relative risk [RR] 1.89, 95%confidence interval [CI] 1.13-3.15) and risk of pseudoan-
eurysm over five times as high (RR 5.40, 95% CI 1.21-
24.5) in patients who received a closure device as compared
with those who received manual compression.
Our study demonstrates several potential strategies
used in improving outcomes associated with percutaneous
arterial closure in patients with peripheral vascular disease.
First, we used fewer closure devices, and used them more
effectively with fewer failures, likely because our protocol
limited use in patients with extensive scarring or calcifica-
tion. Does using fewer closure devices constitute “improve-
ment”? If these devices are used more effectively, we would
argue yes. Closure devices, while popular for decreasing
time to hemostasis and ambulation, have been described as
having only “marginal evidence” to support their effective-
ness,4 add significant cost to already costly procedures7 and
have been subject to a broad range of complications.5,6
Therefore, we consider judicious and efficacious use of
these devices to certainly be an important marker of a
successful quality improvement initiative.
Second, our protocol design and implementation rep-
resents a quality improvement method called a Deming
cycle, or PDSA (plan, do, study, act) cycle.11 By planning
an intervention, implementing it, and studying the out-
come, we changed the processes of care surrounding per-
cutaneous arterial closure and also improved our results.
Some of these changes in processes of care were intentional
and contained within the protocol, such as standardized
manual compression times and limiting closure device use
to patients with normal femoral arteries. However, to our
surprise, implementation of the protocol also caused several
changes that were not overtly described within the protocol
itself. Manual compression times were slightly longer in the
postprotocol phase. Heparin went unreversed fewer times
in the postprotocol phase. A hemostatic patch was used
more often in the postprotocol phase, either alone or as an
adjunct to a closure device. Why did these changes occur,
even without being specifically outlined in the protocol?
Perhaps, while studying the particular processes of care
documented in the protocol, surgeons may have consid-
ered other changes in process of care aimed towards im-
proving outcomes. This use of continuous quality improve-
ment initiatives has been well described in healthcare,
especially in surgical procedures.15,16 Or, perhaps simply by
studying the process itself, instead of implementing any
specific intervention, we improved our results, a phenom-
enon described as the Hawthorne effect.11
The Hawthorne effect was first described in a Harvard
Business School study in the late 1920s of the Hawthorne
Plant of the Western Electric Company, wherein after
examining the physical and environmental aspects of a
workplace, the study authors concluded that group perfor-
mance, informal organizational structure, and social influ-
ences within a system are important determinants of the
results obtained by a system. These conclusions formed the
basis for the study of human relationships within an orga-
nization, and it still remains an important influence in
quality improvement initiatives developed today. Given the
JOURNAL OF VASCULAR SURGERY
Volume 48, Number 6 Goodney et al 1487complexity and team-based approach to modern vascular
surgery, it is easy to understand why quality improvement
initiatives that address these tenets would offer opportunity
for improvement in outcomes.
And finally, eliminating unnecessary variation within
the “system” of arterial closure may have contributed to
our results. Our clinical pathway limited variation and
standardized our closure methods after peripheral arterial
interventions. Several studies have demonstrated that re-
ducing variation in health care can improve outcomes in a
broad variety of health care settings.17-19 Therefore, while
our closure protocol focused on a few specific elements in
an effort to improve results, one might also argue that our
quality improvement initiative help to spur interest and
initiative to achieve the best outcomes, resulting in measur-
able improvement.
Our study has several limitations. First, our study is not,
and was not designed to be, a randomized trial comparing
closure devices and manual compression. Rather, it was our
goal to study the effect of our protocol on closure methods
and outcomes. Therefore, the relative complications rates
of manual compression and closure devices in achieving
hemostasis should be interpreted with caution. Second,
femoral artery calcification was an important decision
branch in our protocol. However, “femoral calcification”
was recorded as a categorical (yes/no) variable. In other
words, this was a subjective determination made upon
radiologic examination of the femoral artery, either on
preoperative computed tomography (CT) findings or an-
giographic visualization during the procedure itself. We
know of no scale or description that allows grading of the
calcifications in the artery, even though it stands to reason
that a femoral artery with a small amount of posterior
plaque would be less likely to be difficult to close as com-
pared to a circumferentially calcified, heavily calcified vessel.
The relative effect of differential calcification on our out-
come, however, is unknown. Third, while complication
rates were lower in the postprotocol phase of the study,
there were no significant differences in the necessity of
additional maneuvers or interventions, and there were no
significant differences in the need for transfusion between
the two phases. The lack of differences in these findingsmay
be attributable to type II error. This finding would not be
altogether surprising, as our power analysis focus on overall
complication rates, not necessarily each individual type of
complication.
In conclusion, we designed and implemented a proto-
col to standardize and improve outcomes in percutaneous
arterial closure in patients with peripheral vascular disease.
We found that our protocol, based on sheath size, arterial
calcification, and previous access scarring, improved patient
selection for closure device use and decreased minor com-
plications associated with percutaneous arterial closure.
Moreover, our study demonstrates the utility and applica-
bility of quality improvement initiatives in improving out-
comes in vascular surgery.AUTHOR CONTRIBUTIONS
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RECOUP THE LOUPES 
Despite extremely limited resources, surgeons in developing countries work to provide their 
patients with the best possible care. For many of these surgeons, technology such as loupes, 
which facilitate delicate procedures, is simply out of reach.  
One year ago, Loupes Around The World distributed its first pair of loupes to a plastic surgeon
in Phnom Penh, Cambodia. Before Loupes Around The World, this surgeon commonly 
repaired cleft lips and palates, and treated trauma patients with maxillofacial injuries without 
the benefit of surgical magnification. Since then, this not-for-profit organization has provided 
loupes to surgeons from Panama to India and continues to receive requests from surgeons 
around the world.  
Loupes Around The World is now recycling donated loupes via a program called “Recoup the 
Loupes.” Surgeons with unused loupes are asked to send them to the foundation; there, repairs 
can be made to adjustable loupes, and the telescopes from fixed loupes can be installed into 
new lenses and frames. For fixed loupes, optical measurements are taken to ensure that the 
loupes will meet the needs of each individual surgeon. 
Please send your unused loupes to:  
David C. Knight, M.D., F.A.C.S. 
Loupes Around The World 
c/o Surgical Associates of Waterbury 
1211 West Main St. 
Waterbury, CT 06708 
Loupes Around The World accepts loupes made by any manufacturer. For more information 
about Loupes Around The World, as well as information about how to contribute, please visit: 
www.loupesaroundtheworld.org. Upon receiving loupes, a letter of acknowledgment will be 
sent to the donor for tax purposes. Loupes Around the World is a 501(c)3 tax-exempt 
organization.  
